Business
Interim 2026 Results
BSF Enterprise PLC reported a net loss of £956,625 for the six months ending March 31, 2026, an increase from the previous year's loss of £790,623, primarily due to increased R&D investment and operational scaling. The company secured short-term liquidity through a £300,000 convertible loan note and subsequently raised significant capital post-period, including a £1,000,000 Indigo Capital convertible loan note, to support growth through 2026-2027. Strategic progress was made across its portfolio companies, with Lab-Grown Leather reaching technical milestones, 3DBT progressing its CytoBoost™ product range and securing a commercial pipeline with Seawith, and Kerato Ltd advancing its LiQD Cornea™ programme. The company remains focused on commercialisation and clinical execution, with upcoming milestones including product demonstrations and veterinary trial progress. Disclaimer*
About this update from Bsf Enterprise Plc
30 June 2026 BSF Enterprise PLC ("BSF" or the "Company") Interim 2026 Results BSF (LSE: BSFA), (OTCQB: BSFAF), a leading innovator in tissue-engineered materials is pleased to announce its unaudited interim results for the six months ending 31 March 2026. Key Highlights ● Strategic Progress: Advanced portfolio companies: Lab-Grown Leather (LGL) reached technical milestones with Elemental X™; 3DBT progressed CytoBoost™ product range and secured a commercial pipeline with Seawith; Kerato Ltd advanced the LiQD Cornea™ programme. ● Financial Performance: Net loss of £956,625 for the period ended 31 March 2026, reflecting investment in R&D and scaling. ● Capital & Funding: Secured short-term liquidity through a £300,000 convertible loan note (CLN). Post-period, raised significant capital via share placements and a £1,000,000 Indigo Capital CLN to support 2026-2027 growth. ● Outlook: Focused on commercialisation and clinical execution. Key upcoming milestones include product demonstrations for T-Rex Leather™, veterinary trial progress for Kerato, and expanding the 3DBT biopharma/cultivated meat pipeline. Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here: https://bsfenterprise.com/link/ya28Ke For further enquiries, please visit www.bsfenterprise.com or contact: BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website. https://bsfenterprise.com/s/a1f22b Bowsprit Partners John Treacy James Sheehan +44 (0)203 883 4430 ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5. Registered number: 11554014 BSF Enterprise Plc Unaudited Interim Consolidated Financial Statements for the period ended...
View stock analysis, news, and events for Bsf Enterprise Plc